Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
06
11
2020
accepted:
04
02
2021
pubmed:
17
3
2021
medline:
28
9
2021
entrez:
16
3
2021
Statut:
ppublish
Résumé
As the population at risk for pelvic nodal involvement remains poorly described, the role of pelvic lymphadenectomy (LAE) in vulvar squamous cell cancer (VSCC) has been a matter of discussion for decades. In the AGO-CaRE-1 study, 1618 patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB or higher primary VSCC treated at 29 centers in Germany between 1998 and 2008 were documented. In this analysis, only patients with pelvic LAE (n = 70) were analyzed with regard to prognosis and correlation between inguinal and pelvic lymph node involvement. The majority of patients had T1b/T2 tumors (n = 47; 67.1%), with a median diameter of 40 mm (2-240 mm); 54/70 patients (77.1%) who received pelvic LAE had positive groin nodes. For 42 of these 54 patients, the number of affected groin nodes had been documented as a median of 3; 14/42 (33.3%) of these patients had histologically confirmed pelvic nodal metastases (median number of affected pelvic nodes 3 [1-12]). In these 14 patients, the median number of affected groin nodes was 7 (1-30), with a groin metastases median maximum diameter of 42.5 mm (12-50). Receiver operating characteristic analysis showed an area under the curve of 0.85, with 83.3% sensitivity and 92.6% specificity for the prediction of pelvic involvement in cases of six or more positive groin nodes. No cases of pelvic nodal involvement without groin metastases were observed. Prognosis in cases of pelvic metastasis was poor, with a median progression-free survival of only 12.5 months. For the majority of node-positive patients with VSCC, pelvic nodal staging appears unnecessary since a relevant risk for pelvic nodal involvement only seems to be present in highly node-positive disease.
Sections du résumé
BACKGROUND
BACKGROUND
As the population at risk for pelvic nodal involvement remains poorly described, the role of pelvic lymphadenectomy (LAE) in vulvar squamous cell cancer (VSCC) has been a matter of discussion for decades.
METHODS
METHODS
In the AGO-CaRE-1 study, 1618 patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB or higher primary VSCC treated at 29 centers in Germany between 1998 and 2008 were documented. In this analysis, only patients with pelvic LAE (n = 70) were analyzed with regard to prognosis and correlation between inguinal and pelvic lymph node involvement.
RESULTS
RESULTS
The majority of patients had T1b/T2 tumors (n = 47; 67.1%), with a median diameter of 40 mm (2-240 mm); 54/70 patients (77.1%) who received pelvic LAE had positive groin nodes. For 42 of these 54 patients, the number of affected groin nodes had been documented as a median of 3; 14/42 (33.3%) of these patients had histologically confirmed pelvic nodal metastases (median number of affected pelvic nodes 3 [1-12]). In these 14 patients, the median number of affected groin nodes was 7 (1-30), with a groin metastases median maximum diameter of 42.5 mm (12-50). Receiver operating characteristic analysis showed an area under the curve of 0.85, with 83.3% sensitivity and 92.6% specificity for the prediction of pelvic involvement in cases of six or more positive groin nodes. No cases of pelvic nodal involvement without groin metastases were observed. Prognosis in cases of pelvic metastasis was poor, with a median progression-free survival of only 12.5 months.
CONCLUSION
CONCLUSIONS
For the majority of node-positive patients with VSCC, pelvic nodal staging appears unnecessary since a relevant risk for pelvic nodal involvement only seems to be present in highly node-positive disease.
Identifiants
pubmed: 33723714
doi: 10.1245/s10434-021-09744-y
pii: 10.1245/s10434-021-09744-y
pmc: PMC8460538
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6696-6704Informations de copyright
© 2021. The Author(s).
Références
Boyce J, Fruchter RG, Kasambilides E, Nicastri AD, Sedlis A, Remy JC. Prognostic factors in carcinoma of the vulva. Gynecol Oncol. 1985;20(3):364–77. https://doi.org/10.1016/0090-8258(85)90218-5 .
doi: 10.1016/0090-8258(85)90218-5
pubmed: 3972295
Hacker NF, van der Velden J. Conservative management of early vulvar cancer. Cancer. 1993;71(4 Suppl):1673–7.
doi: 10.1002/cncr.2820710436
Klemm P, Marnitz S, Köhler C, Braig U, Schneider A. Clinical implication of laparoscopic pelvic lymphadenectomy in patients with vulvar cancer and positive groin nodes. Gynecol Oncol. Oct ;99(1):101–5. https://doi.org/10.1016/j.ygyno.2005.05.027 .
doi: 10.1016/j.ygyno.2005.05.027
pubmed: 15982723
van der Velden J, van Lindert AC, Lammes FB. Extracapsular growth of lymph node metastases in squamous cell carcinoma of the vulva. The impact on recurrence and survival. Cancer. 1995;75(12):2885–90.
doi: 10.1002/1097-0142(19950615)75:12<2885::AID-CNCR2820751215>3.0.CO;2-3
Homesley HD, Bundy BN, Sedlis A, Adcock L. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol. Dec ;68(6):733–40.
pubmed: 3785783
Hacker NF, Eifel PJ, van der Velden J. Cancer of the vulva. Int J Gynaecol Obstet. Oct ;131(Suppl 2):S76-83. https://doi.org/10.1016/j.ijgo.2015.06.002 .
doi: 10.1016/j.ijgo.2015.06.002
pubmed: 26433678
National German Guideline S2k. Diagnosis, Therapy, and Follow-Up Care of Vulvar Cancer and its Precursors, AWMF Registry No. 015/059. http://www.awmf.org/leitlinien/Diagnose,TherapieundNachsorgedesVulvakarzinomsundseinerVorstufen/ii/015-059.html
Hacker NF, Berek JS, Lagasse LD, Leuchter RS, Moore JG. Management of regional lymph nodes and their prognostic influence in vulvar cancer. Obstet Gynecol. Apr ;61(4):408–12.
pubmed: 6828268
Curry SL, Wharton JT, Rutledge F. Positive lymph nodes in vulvar squamous carcinoma. Gynecol Oncol. Feb ;9(1):63–7. https://doi.org/10.1016/0090-8258(80)90009-8 .
doi: 10.1016/0090-8258(80)90009-8
pubmed: 7353802
Mahner S, Jueckstock J, Hilpert F, et al. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst. 2015;107(3):dju426. https://doi.org/10.1093/jnci/dju426 .
doi: 10.1093/jnci/dju426
pubmed: 25618900
pmcid: 4356703
American Joint Commission on Cancer. AJCC Cancer Staging Manual. 6th ed. 2002. https://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx . Accessed 10 Nov 2014.
Union for International Cancer Control. TNM classification of malignant tumours. New York: Wiley; 2002.
Mitra S, Sharma MK, Kaur I, et al. Vulvar carcinoma: dilemma, debates, and decisions. Cancer Manag Res. 2018;10:61–8. https://doi.org/10.2147/CMAR.S143316 .
doi: 10.2147/CMAR.S143316
pubmed: 29386916
pmcid: 5765975
Papadia A, Ehm L, Gasparri ML, Wang J, Radan AP, Mueller MD. Unilateral versus bilateral lymph-nodal metastases and oncologic outcome in vulvar cancer patients. J Cancer Res Clin Oncol. 2020;146(7):1877–81. https://doi.org/10.1007/s00432-020-03196-9 .
doi: 10.1007/s00432-020-03196-9
pubmed: 32266536
Woelber L, Eulenburg C, Choschzick M, et al. Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment. Int J Gynecol Cancer. 2012;22(3):503–8. https://doi.org/10.1097/IGC.0b013e31823eed4c .
doi: 10.1097/IGC.0b013e31823eed4c
pubmed: 22266935
Oonk MH, van Hemel BM, Hollema H, et al. Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol. 2010;11(7):646–52. https://doi.org/10.1016/S1470-2045(10)70104-2 .
doi: 10.1016/S1470-2045(10)70104-2
pubmed: 20537946
Abang Mohammed DK, Uberoi R, Lopes ADB, Monaghan JM. Inguinal node status by ultrasound in vulva cancer. Gynecol Oncol. 2000;77(1):93–6. https://doi.org/10.1006/gyno.1999.5702 .
doi: 10.1006/gyno.1999.5702
pubmed: 10739696
Hawnaur JM, Reynolds K, Wilson G, Hillier V, Kitchener HC. Identification of inguinal lymph node metastases from vulval carcinoma by magnetic resonance imaging: an initial report. Clin Radiol. 2002;57(11):995–1000. https://doi.org/10.1053/crad.2002.1057 .
doi: 10.1053/crad.2002.1057
pubmed: 12409110
Cohn DE, Dehdashti F, Gibb RK, et al. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol. 2002;85(1):179–84. https://doi.org/10.1006/gyno.2002.6605 .
doi: 10.1006/gyno.2002.6605
pubmed: 11925141
de Gregorio N, Ebner F, Schwentner L, et al. The role of preoperative ultrasound evaluation of inguinal lymph nodes in patients with vulvar malignancy. Gynecol Oncol. 2013;131(1):113–7. https://doi.org/10.1016/j.ygyno.2013.07.103 .
doi: 10.1016/j.ygyno.2013.07.103
pubmed: 23932893